Thanks for sharing.It was such a solid move bringing on the two...

Thanks for sharing.

It was such a solid move bringing on the two authorities in the space of wearables to our advisory board. They know the ins and outs of the competition and when needs to be done to create a heart diagnostic wearable that will read out meaningful, medically useful data.

Will only bode well for when Conneqt Band goes for FDA approval and once approved the revenue implications for the Conneqt platform can’t be understated. Medicare rebates on the device and the subscriptions alone will be huge.

Thinking out loud, I’d imagine CC and the team will be wanting to leverage FDA approval of the Pulse prior to dual listing, that’d make the most sense in my mind. Should also mean we’d be raising capital to US based investors at a much higher SP than we’re at currently. FDA approval will be the first significant inflection point for CDX in a while and its genuinely value adding so I’d expect a decent rerate and a new base to form.

Assuming no nasty surprises in global markets we should be in for an exciting few months. Here’s hoping.

IMO DYO